CATALYST PHARMACEUTICALS, INC.: net inventory
Net inventory for CATALYST PHARMACEUTICALS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All CATALYST PHARMACEUTICALS, INC. financial histories
What this measure means
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
Exact concept: us-gaap:InventoryNet. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2017-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 37,166,000 | USD | 2026-02-25 | 10-K · 0001193125-26-071525 |
| At date | 2024-12-31 | 19,541,000 | USD | 2026-02-25 | 10-K · 0001193125-26-071525 |
| At date | 2023-12-31 | 15,644,000 | USD | 2025-02-26 | 10-K · 0000950170-25-027714 |
| At date | 2022-12-31 | 6,805,000 | USD | 2024-02-28 | 10-K · 0001193125-24-050908 |
| At date | 2021-12-31 | 7,870,000 | USD | 2023-03-15 | 10-K · 0001193125-23-071299 |
| At date | 2020-12-31 | 4,651,000 | USD | 2022-03-16 | 10-K · 0001193125-22-077228 |
| At date | 2019-12-31 | 1,956,792 | USD | 2021-03-15 | 10-K · 0001193125-21-081545 |
| At date | 2018-12-31 | 56,012 | USD | 2020-03-16 | 10-K · 0001193125-20-075048 |
| At date | 2017-12-31 | 0 | USD | 2019-03-18 | 10-K · 0001193125-19-078253 |
Related financial histories
- CATALYST PHARMACEUTICALS, INC.: total assets
- CATALYST PHARMACEUTICALS, INC.: total liabilities
- CATALYST PHARMACEUTICALS, INC.: stockholders equity
- CATALYST PHARMACEUTICALS, INC.: cash and cash equivalents
- CATALYST PHARMACEUTICALS, INC.: net income or loss
- CATALYST PHARMACEUTICALS, INC.: operating cash flow
- CATALYST PHARMACEUTICALS, INC.: capital expenditure payments
- CATALYST PHARMACEUTICALS, INC.: revenue
- CATALYST PHARMACEUTICALS, INC.: contract revenue excluding tax
- CATALYST PHARMACEUTICALS, INC.: financing cash flow
- CATALYST PHARMACEUTICALS, INC.: investing cash flow
- CATALYST PHARMACEUTICALS, INC.: retained earnings or deficit
- CATALYST PHARMACEUTICALS, INC.: basic weighted-average shares
- CATALYST PHARMACEUTICALS, INC.: diluted weighted-average shares
- CATALYST PHARMACEUTICALS, INC.: basic earnings per share
- CATALYST PHARMACEUTICALS, INC.: diluted earnings per share
- CATALYST PHARMACEUTICALS, INC.: income tax expense or benefit
- CATALYST PHARMACEUTICALS, INC.: net property, plant and equipment
- CATALYST PHARMACEUTICALS, INC.: share-based compensation expense
- CATALYST PHARMACEUTICALS, INC.: operating income or loss
- CATALYST PHARMACEUTICALS, INC.: current assets
- CATALYST PHARMACEUTICALS, INC.: current liabilities
- CATALYST PHARMACEUTICALS, INC.: current accounts payable
- CATALYST PHARMACEUTICALS, INC.: net finite-lived intangible assets
- CATALYST PHARMACEUTICALS, INC.: net current accounts receivable
- CATALYST PHARMACEUTICALS, INC.: common-stock repurchase payments
- CATALYST PHARMACEUTICALS, INC.: operating expenses
- CATALYST PHARMACEUTICALS, INC.: selling, general and administrative expense
- CATALYST PHARMACEUTICALS, INC.: research and development expense
- CATALYST PHARMACEUTICALS, INC.: common shares outstanding
- CATALYST PHARMACEUTICALS, INC.: cash including restricted cash
- CATALYST PHARMACEUTICALS, INC.: additional paid-in capital
- CATALYST PHARMACEUTICALS, INC.: accumulated other comprehensive income or loss
- CATALYST PHARMACEUTICALS, INC.: operating lease right-of-use asset
- CATALYST PHARMACEUTICALS, INC.: operating lease liability
- CATALYST PHARMACEUTICALS, INC.: gross property, plant and equipment
- CATALYST PHARMACEUTICALS, INC.: accumulated depreciation on property, plant and equipment
- CATALYST PHARMACEUTICALS, INC.: other noncurrent liabilities
- CATALYST PHARMACEUTICALS, INC.: accrued current liabilities
- CATALYST PHARMACEUTICALS, INC.: prepaid expenses and other current assets
- CATALYST PHARMACEUTICALS, INC.: net deferred tax assets
- CATALYST PHARMACEUTICALS, INC.: pre-tax income or loss from continuing operations
- CATALYST PHARMACEUTICALS, INC.: profit or loss including noncontrolling interests
- CATALYST PHARMACEUTICALS, INC.: comprehensive income or loss
- CATALYST PHARMACEUTICALS, INC.: general and administrative expense
- CATALYST PHARMACEUTICALS, INC.: depreciation expense
- CATALYST PHARMACEUTICALS, INC.: depreciation, depletion and amortization
- CATALYST PHARMACEUTICALS, INC.: amortization of intangible assets
- CATALYST PHARMACEUTICALS, INC.: other nonoperating income or expense
- CATALYST PHARMACEUTICALS, INC.: current income tax expense or benefit
- CATALYST PHARMACEUTICALS, INC.: deferred income tax expense or benefit
- CATALYST PHARMACEUTICALS, INC.: interest paid, net
- CATALYST PHARMACEUTICALS, INC.: proceeds from issuing common stock
- CATALYST PHARMACEUTICALS, INC.: operating lease payments
- CATALYST PHARMACEUTICALS, INC.: change in accounts receivable
- CATALYST PHARMACEUTICALS, INC.: change in inventories
- CATALYST PHARMACEUTICALS, INC.: change in accounts payable
Inspect the source
- Entity
- CATALYST PHARMACEUTICALS, INC. / CIK 0001369568
- Captured
- 2026-09-21T17:19:25.463Z
- SEC response SHA-256
7cf76a511a9127dd31ed7d53955bbe348f790d8d7fd354d359e6674e7b2af9c9
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001369568.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))